Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBIO-610 in Overweight or Obese Adult Participants
NCT07890870Phase 1Not yet recruiting
- Sponsor
- iBio
- Start
- Dec 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anti-Activin E antibody in obesity (5 arms), sponsored by iBio. Primary endpoint: Incidence, severity, and relationship to study treatment of Treatment-Emergent Adverse Events and Serious Adverse Events. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
anti-Activin E antibody
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07890870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890870.